AMAM

Ambrx Biopharma Inc. (AMAM) | Rumor.io

Ambrx Biopharma

AMAM

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about AMAM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 17

$AMAM was acquired and its price increased from $0.40 to $28 per share.
One analyst has a price target of $23 for $AMAM.
Some analysts have set a high price target for $AMAM, but the exact figure is not specified.

Generated by AI

Sentiment

Of the messages about AMAM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +8.91
Bearish	—	—	—	0% -8.91

Bullish· Jan 8

$AMAM has experienced a remarkable rise, increasing from $0.50 in December 2022 to $27, a 56x return on the acquisition price by Johnson & Johnson.
The stock's acquisition by Johnson & Johnson for $2 billion represents a significant turnaround for Ambrx Biopharma, which was previously a penny stock.
The company's acquisition and subsequent price increase have led to significant short-selling losses, with 6 million short shares losing over $80 million.

Bearish· Oct 16

The company's stock price was halted at $10, and the price was held under $9.90 all day until the close when it popped to $12.15.
The stock price dropped 48% for no apparent reason, and the author believes it was a scam.
The stock's massive reversal of -7% was seen as a typical "sell the news" move, with the author expecting a short attack to recover.

Generated by AI

Topics

Of the messages about AMAM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	92.31%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	7.69%

Announcements· Jan 9

Ambrx Biopharma Inc. ($AMAM) is being acquired by Johnson & Johnson ($JNJ) for $20 billion in cash.
The acquisition provides JNJ with access to Ambrx's targeted cancer therapies, which have shown good efficacy with minimal side effects.
Ambrx's lead drug targets prostate cancer, a significant market opportunity, and the company is also developing treatments for other types of cancer.

Technical Analysis· Mar 8

$AMAM has broken above resistance around $0.35, accelerating to new highs.
A bullish engulfing candle is forming, with a target of $11.25 for the day.
The stock has flowed off a 13D increase to 26.4%, with a 10.15+ intraday breakout and 10.55+ to set the hourly heat.

Generated by AI

Community

Of the messages about AMAM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	72.41%
Newcomers	—	—	—	27.59%

Regulars· Jan 8

Johnson & Johnson's acquisition of Ambrx Biopharma for $2 billion is advancing next-generation antibody drug conjugates to transform cancer treatment.
Ambrx Biopharma's data at ESMO23 caused initial skepticism, but Johnson & Johnson saw potential and acquired the company, with many biotech stocks experiencing a positive reaction.
Cantor has expressed strong conviction in Ambrx Biopharma, and the company's stock has seen significant gains, with some investors achieving a 167% profit in a short period.

Newcomers· Jan 9

Many newcomers are interested in the recent price action of $AMAM, with some noticing a significant increase in value.
There is a strong focus on the acquisition of Ambrx Biopharma by Johnson & Johnson, with many users discussing the terms and implications of the deal.
Some users are highlighting the potential benefits of Ambrx Biopharma's cancer-targeting therapies and the company's potential as a pharmaceutical play.

Generated by AI

Also Discussed

Investors talking about AMAM also mention

#	Name	Attention
1	Pharvaris N.V. Ordinary SharesPHVS	0%0
2	HARP - Harpoon Therapeutics, Inc.	——
3	Cosmos Health Inc.COSM	0.02%+0.01
4	ComSovereign Holding Corp.COMS	0%new
5	ICVX - Icosavax, Inc.	——
6	HPCO - Hempacco Co., Inc.	——
7	MGAM - Mobile Global Esports Inc.	——
8	Summit Therapeutics Inc.SMMT	0.05%-0.04
9	ZVSA - ZyVersa Therapeutics, Inc.	——
10	Sera Prognostics, Inc. Class A Common StockSERA	0%0

Ambrx Biopharma Inc.

Location

Social

What share of all stock conversation is about AMAM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 17

$AMAM was acquired and its price increased from $0.40 to $28 per share.
One analyst has a price target of $23 for $AMAM.
Some analysts have set a high price target for $AMAM, but the exact figure is not specified.

Generated by AI

Sentiment

Of the messages about AMAM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +8.91
Bearish	—	—	—	0% -8.91

Bullish· Jan 8

$AMAM has experienced a remarkable rise, increasing from $0.50 in December 2022 to $27, a 56x return on the acquisition price by Johnson & Johnson.
The stock's acquisition by Johnson & Johnson for $2 billion represents a significant turnaround for Ambrx Biopharma, which was previously a penny stock.
The company's acquisition and subsequent price increase have led to significant short-selling losses, with 6 million short shares losing over $80 million.

Bearish· Oct 16

The company's stock price was halted at $10, and the price was held under $9.90 all day until the close when it popped to $12.15.
The stock price dropped 48% for no apparent reason, and the author believes it was a scam.
The stock's massive reversal of -7% was seen as a typical "sell the news" move, with the author expecting a short attack to recover.

Generated by AI

Topics

Of the messages about AMAM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	92.31%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	7.69%

Announcements· Jan 9

Ambrx Biopharma Inc. ($AMAM) is being acquired by Johnson & Johnson ($JNJ) for $20 billion in cash.
The acquisition provides JNJ with access to Ambrx's targeted cancer therapies, which have shown good efficacy with minimal side effects.
Ambrx's lead drug targets prostate cancer, a significant market opportunity, and the company is also developing treatments for other types of cancer.

Technical Analysis· Mar 8

$AMAM has broken above resistance around $0.35, accelerating to new highs.
A bullish engulfing candle is forming, with a target of $11.25 for the day.
The stock has flowed off a 13D increase to 26.4%, with a 10.15+ intraday breakout and 10.55+ to set the hourly heat.

Generated by AI

Community

Of the messages about AMAM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	72.41%
Newcomers	—	—	—	27.59%

Regulars· Jan 8

Johnson & Johnson's acquisition of Ambrx Biopharma for $2 billion is advancing next-generation antibody drug conjugates to transform cancer treatment.
Ambrx Biopharma's data at ESMO23 caused initial skepticism, but Johnson & Johnson saw potential and acquired the company, with many biotech stocks experiencing a positive reaction.
Cantor has expressed strong conviction in Ambrx Biopharma, and the company's stock has seen significant gains, with some investors achieving a 167% profit in a short period.

Newcomers· Jan 9

Many newcomers are interested in the recent price action of $AMAM, with some noticing a significant increase in value.
There is a strong focus on the acquisition of Ambrx Biopharma by Johnson & Johnson, with many users discussing the terms and implications of the deal.
Some users are highlighting the potential benefits of Ambrx Biopharma's cancer-targeting therapies and the company's potential as a pharmaceutical play.

Generated by AI

Ambrx Biopharma

Social

Jan 17

Sentiment

Bullish· Jan 8

Bearish· Oct 16

Topics

Announcements· Jan 9

Technical Analysis· Mar 8

Community

Regulars· Jan 8

Newcomers· Jan 9

Also Discussed

Ambrx Biopharma Inc.

Company Information

Location

Also Discussed

Social

Jan 17

Sentiment

Bullish· Jan 8

Bearish· Oct 16

Topics

Announcements· Jan 9

Technical Analysis· Mar 8

Community

Regulars· Jan 8

Newcomers· Jan 9